Mr. Raad was appointed Chief Executive Officer in 2019. Prior to his appointment, he served as PULMATRiX’s Chief Business Officer and led commercial and business development efforts. He has 20 years of commercial healthcare and life science ...see more leadership experience and most recently served as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider. Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD. During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the US and Japan. Earlier in his career, he also gained direct launch experience with Sporanox®, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the PULMATRiX PUR1900 program. Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management. ...see less
Ms. Siegert is responsible for the corporate finance function and is the principal finance and accounting officer for PULMATRiX. Since Ms. Siegert joined the company in 2010, she has progressed through numerous roles of increasing responsibility. ...see more She began her finance career at W.R. Grace & Co. and has completed more than 25 years of financial, transactional, and operational experience in both private and public companies. Ms. Siegert holds a Bachelor of Arts degree in Management with a concentration in Accounting from Simmons University. ...see less
Dr. Curran has had responsibility for the oversight of all nonclinical and translational research since joining Pulmatrix in 2015. He worked previously as Director of Inhalation Toxicology at Huntingdon Life Sciences and, previous to that, as an Associate Principle Scientist at the Schering-Plough Research Institute in their Pulmonary and Peripheral Neurobiology Department. ...see more Prior to his more than 15 years of pharmaceutical experience, Dr. Curran spent over a decade in academic research, predominantly at the University of Wisconsin at Madison and Dartmouth Medical School and has more than 30 peer reviewed manuscripts in the area of respiratory neurobiology and pulmonary disease. Dr Curran received his undergraduate and graduate degrees in Pulmonary Physiology from the National University of Ireland. ...see less
Mr. Perry is responsible for technical development of PULMATRiX’s product pipeline, including formulation development, process development, analytical development and manufacturing. ...see more Mr. Perry has 15 years of experience developing pharmaceutical products. Prior to joining Pulmatrix in 2012, he held formulation and process development roles at Alkermes, advancing oral, inhalation and parenteral dosage form products through early and late-phase development. He holds a BS in Chemical Engineering from the University of Massachusetts, Amherst. ...see less
Mr. Kramer is responsible for the Quality function in addition to overseeing the safety and facilities functions at PULMATRIX. Since joining the company in 2009, Mr. Kramer has progressed through numerous roles of increasing responsibility. ...see more Prior to joining PULMATRIX, Mr. Kramer held position at Alkermes and AMAG Pharmaceutical and has over 15 years of experience in the pharmaceutical industry supporting the Quality Assurance and Quality Control functions. Mr. Kramer holds a Bachelor of Science degree in Forensic Toxicology from John Jay College of Criminal Justice and a Master of Science degree in Pharmaceutical Biotechnology from Northeastern University. ...see less
Mr. Ludlum is an experienced financial executive with over 23 years of work with early-stage and high growth companies within the life science sector. He is currently a Senior Director at Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies and Mr. Ludlum serves as the Strategic Advisor – Finance for Pulmatrix. ...see more
Previously, Mr. Ludlum has served in the roles of Co-President, Chief Business Officer, Chief Financial Officer, Financial Compliance Officer, and Group Controller at pharmaceutical, medical device and diagnostic products and reference laboratory companies.
Mr. Ludlum holds a B.S. in Business and Economics with a major in accounting from Lehigh University and a Masters in Business Administration with a concentration in Finance from California State University, Fullerton. ...see less
Dr. Lipp is currently the Senior Vice President of Pharmaceutical Development at Nocion Therapeutics Inc., a biotech startup focusing on the development of novel drug candidates (“Nocions”) for the treatment of various conditions related to pain and itch. He has over two ...see more
decades of experience in pharmaceutical development and drug delivery technologies ranging from the preclinical stage through commercial approval. Prior to joining Nocion, Dr. Lipp was head of Pharmaceutical Development at Civitas Therapeutics through its acquisition by Acorda Therapeutics. At Acorda, Dr. Lipp was Site Head of the Acorda Waltham R&D Facility and led the efforts related to the Chemistry, Manufacturing and Control (CMC) activities associated with Inbrija™ which was approved by the FDA in 2018 as the first in-class treatment for OFF episodes in Parkinson’s Disease.
Dr. Lipp was previously the Vice President of Pharmaceutical Development and Intellectual Property at PULMATRiX where he was a co-inventor of the iSPERSE™ technology. Prior to PULMATRiX, Dr. Lipp was Director of Formulation Development at Alkermes, managing and directing formulation and pharmaceutical development activities related to pulmonary, injectable, and oral platforms. Dr. Lipp began his career as a Post-Doctoral Fellow working with Advanced Inhalation Research (AIR®), where he became a Staff Scientist focusing on pulmonary product development prior to its acquisition by Alkermes.
Dr. Lipp received his B.Sc. in Chemical Engineering from Cornell University and his Ph.D. in Chemical Engineering and Materials Science from the University of California, Santa Barbara. Dr. Lipp pursued a NIH Postdoctoral Fellowship at the Massachusetts Institute of Technology in the laboratory of Professor Robert S. Langer (one of the Founders of AIR), where he remains a Research Affiliate. ...see less
Dr Wasilewski leverages over 25 years of experience in pharmaceutical drug development. She led the clinical development program for treatment and recurrence prevention in Clostridioides difficile infection as Vice President Research and Development-Medical at Summit Therapeutics. ...see more Dr. Wasilewski held various leadership roles at Eli Lilly and Company, Targanta Therapeutics, and Shire. Her clinical development experience includes bacterial and viral infections, sepsis, neurology, and rare disease. As President of ID Remedies, LLC, she has provided scientific, medical, and regulatory consultation and business development to various biopharmaceutical companies.
Dr. Wasilewski received a medical degree from Tufts University School of Medicine. She is board certified in Internal Medicine and completed fellowships in Infectious Diseases and Clinical Pharmacology at the University of California-San Francisco. Dr. Wasilewski received an MBA from Indiana University, Kelly School of Business; a master’s degree in Nutrition from the University of California-Berkeley and an undergraduate degree in Chemistry from Rutgers University. ...see less